ArQule +48.3% AH, DMC recommends continuation of Phase III METIV-HCC trial


The DMC of ArQule's (ARQL) Phase III METIV-HCC trial in hepatocellular carcinoma recommends the continuation of the trial following a review of the data.

The data analyses among patients treated with 120 mg BID tivantinib tablets showed a reduced incidence of neutropenia.

Analyses also demonstrated that plasma exposure of the lower dose was comparable to that achieved with the 240 mg capsules employed in the Phase II trial.

ARQL +48.3% AH

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs